- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Seer was founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer, based on nanoparticle technologies developed in Farokhzad’s laboratory at Brigham and Women’s Hospital, Harvard Medical School. Early investors included Maverick Capital, aMoon Fund, Wing VC, T. Rowe Price, and Fidelity.
In September 2020, Seer spun off PrognomiQ to focus on clinical applications, such as developing a liquid biopsy blood test for early lung cancer detection. Philip Ma became President and CEO of PrognomiQ. Farokhzad serves as chair of the board of directors of PrognomiQ. Seer retains approximately 19% ownership in the company.
On December 4, 2020, Seer completed its initial public offering, raising approximately $336.2 million in proceeds. Underwriters included J.P. Morgan, Morgan Stanley, Bank of America Securities, and Cowen.
Seer launched the Proteograph Product Suite in January 2021, which included the SP100 automation instrument and the Proteograph RISE assay kit. In June 2023, the company introduced the Proteograph XT assay kit, which increased system throughput by 150%.
In May 2025, Seer released a high-throughput version of the Proteograph Product Suite, including the Proteograph ONE Assay and SP200 Automation Instrument. The system supports processing of up to 1,000 samples per week and is designed for large-scale proteomic studies.